No Data
No Data
Larimar Therapeutics | 10-K: Annual report
William Blair Maintains Larimar Therapeutics(LRMR.US) With Buy Rating
Promising Prospects for Larimar Therapeutics: Buy Rating Affirmed Amid FDA Support and Strong Financial Position
William Blair Sticks to Their Buy Rating for Larimar Therapeutics (LRMR)
Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating
Larimar Preps 2025 BLA For Nomlabofusp As FDA Endorses Skin FXN Metric, OLE And PK Data Update Set For September
felixfella OP : couldn't go up if it was riding on a airplane...